A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
Status and phase
Completed
Phase 4
Conditions
Genital Herpes
Treatments
Drug: Famciclovir
Details and patient eligibility
About
The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes
Exclusion criteria
- Pregnancy
- History of renal dysfunction
- Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid
- Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Crossover Assignment
Masking
Double Blind
Trial contacts and locations
7
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems